Biotechnology
'Sustainable CDMO' Samsung Biologics releases 2022 ESG Report
* Aims to build an eco-friendly business environment and achieve net zero GHG emissions in its operations, moving towards 100% renewable energy. * Details new social contribution activities that strives to support the health of its local communities. * Requires commitment to the Supplier Cod...
2022-07-11 19:00
1964
Industry Empowered by Science: Guangming Science City Lures Talent Globally
SHENZHEN, China, July 8, 2022 /PRNewswire/ -- The 8th Shenzhen Global Shenzhen Entrepreneurs Convention and Guangming Science City Conference kicked off on July 5, and gathered global scientists and leading entrepreneurs together to the southern Chinese city. They're invited to share their perspec...
2022-07-08 15:38
2055
Biotech Startup Noul Releases 2021 Sustainability Report
* Disclose achievement and improvement on economic, social, and environmental commitments * Contain corporate will to take sustainability as its management philosophy since its foundation * Write based on the GRI standards and self-disclose to the DART electronic disclosure system YONGIN, S...
2022-07-08 15:00
2056
NEW EARLY BREAST CANCER DRUG TO REDUCE RISK OF RECURRENCE OR DEATH NOW AVAILABLE IN THE PHILIPPINES
* NERLYNX® (neratinib) is approved by the Food and Drug Administration of the Philippines * Leading regional breast cancer oncologists say the availability of NERLYNX is a 'great step forward' for women inthe Philippines who have been diagnosed with HER2+ early-stage breast cancer * Five-y...
2022-07-08 09:28
1954
SunHo Announces First Patient Dosed in Phase 1/2 Clinical Trial of Two First-in-class Immunocytokines: IAP0971 and IAE0972
NANJING, China, July 7, 2022 /PRNewswire/ -- SunHo BioPharmaceutical Co., Ltd. ("SunHo"), a clinical-stage leading biopharma in immunocytokines with full-set of capabilities from discovery to commercialization, announced that IAP0971 (PD1-IL15 immunocytokine) and IAE0972 (EGFR-IL10 immunocytokine...
2022-07-07 20:00
1690
Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines
GUANGZHOU, China, July 7, 2022 /PRNewswire/ -- Recently, Zhiyi Biotech announced that it has raised$15 million in its B++ funding round. The funds will be used to boost the clinical development of the company's live biotherapeutic products (LBPs) pipelines. It's worth mentioning thatZhiyi has su...
2022-07-07 17:45
1400
WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility
Site Enhances New Modality CRDMO Platform Capacity for Customers SHANGHAI , July 6, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at itsChangzhou campus. The new facility underscores...
2022-07-07 08:00
3764
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, July 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first patient has bee...
2022-07-06 23:00
2279
US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER
SYDNEY, July 6, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia's paxalisib for t...
2022-07-06 19:00
2770
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007
SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ -- Inmagene
Biopharmaceuticals ("Inmagene
2022-07-06 12:00
1704
Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022
Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ($22.4 Million) 4QFY22 Non-GAAP Operating Income Down 4.1% YoY ...
2022-07-06 04:16
3956
EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement
FUKUOKA, Japan, July 5, 2022 /PRNewswire/ -- EditForce, Inc. (Headquarters: Fukuoka, President and CEO: Takashi Ono; hereinafter "EditForce") has entered into a License Agreement (hereinafter "Agreement") with Mitsubishi Tanabe Pharma Corporation (Headquarters:Osaka, Representative Director: Hiro...
2022-07-05 15:00
1783
ClinChoice Raises $150 mm Series E Round Financing, Further Strengthening its Global Services Capabilities
PHILADELPHIA, July 4, 2022 /PRNewswire/ -- Recently, ClinChoice announced the successful completion of its $150 mm Series E round financing. The investment was led by Legend Capital, and co-invested by Taikang Life Insurance, Sherpa Healthcare Partners and existing shareholders, including Lilly A...
2022-07-05 09:20
2118
WuXi Biologics Extends Capabilities to Include Development and cGMP Manufacturing for Microbial-Derived Products
* WuXi Biologics expands its extensive integrated CRDMO services by offering development and cGMP manufacturing for microbial-derived products. HANGZHOU, China, July 4, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing ...
2022-07-05 08:30
2384
Arctic Vision Announces First Patient Enrolled in Phase III Clinical Trial of ARVN003 for Presbyopia
This is the first clinical trial approved in China for presbyopia drugs and Arctic Vision's study marks the first patient enrollment in a Phase III clinical trial for presbyopia drugs inChina. ARVN003 is expected to be the first approved drug for presbyopia inChina. SHANGHAI, July 4, 2022 /PRNew...
2022-07-04 22:14
2399
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061
SHANGHAI, July 4, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256.HK, referred to "Abbisko Therapeutics" hereafter) today announced completion of dosing of the first patient in the Phase 1 clinical trial in advanced solid tumors for ABSK061, which becomes the first high...
2022-07-04 13:34
2053
ReviR Therapeutics Appoints Paul August, Ph.D., as Chief Scientific Officer
SOUTH SAN FRANCISCO, Calif., July 1, 2022 /PRNewswire/ -- ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced the appointment ofPaul August, Ph.D., as the Chief Scientific Officer. "We are thrilled to welcome Dr. August to our team," s...
2022-07-01 22:00
5093
Ascentage Pharma Announces IND Clearance by the US FDA for First-in-Human Study of Novel EED Inhibitor APG-5918
SUZHOU, China and ROCKVILLE, Md., June 29, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel inhibitor of the embryonic ectoderm...
2022-06-30 10:41
1724
iNtRON to Seek a New Clinical Partner for SAL200 Endolysin
* TONABACASE, the first registered INN by WHO for Endolysin * First-in-Class Endolysin-based Drug against Superbugs * US FDA Phase 2 IND Approval for TONABACASE, SAL200 * Roivant has returned the rights for the asset just before the first patient injection BOSTON and SEOUL, South Korea, Jun...
2022-06-28 21:00
1700
Congratulations to Dragon Boat Biopharmaceutical from Sanyou Biopharmaceuticals on the NMPA acceptance of the CLDN 18.2/CD47 bsAb clinical trial application
SHANGHAI, June 25, 2022 /PRNewswire/ -- On June 15, 2022, Dragon Boat announced that its IND application of the innovative anti-CLDN 18.2/CD47 bi-specific antibody (bsAb) injection (R&D code: BC007) was officially accepted by National Medical Products Administration (NMPA) under the acceptance nu...
2022-06-26 08:00
3661
Week's Top Stories
Most Reposted
Alpha Trading Cup 2024 Award Night: Top Trader Achieves Remarkable 315% Profit, as Over 1,149 Competitors Vie for USD 44,000 Prize Pool
[Picked up by 313 media titles]
2024-10-25 18:29
International Golo Mori Jazz 2024: Experience the Harmony of Eastern Indonesia's Exotic Beauty and Romantic Jazz Music
[Picked up by 300 media titles]
2024-10-25 22:48
2024 Malaysia E-commerce Product Selection Expo Reaches Major Milestone Attracting Leading Brands and Businesses From China
[Picked up by 300 media titles]
2024-10-25 07:00
RuggON Showcases Latest Mining Technology at IMARC 2024
[Picked up by 297 media titles]
2024-10-28 14:32
TotalEnergies ENEOS Completes a 1.8 MWp Floating Solar Photovoltaic System Project, a Second Collaboration with S. Kijchai Enterprise in Thailand
[Picked up by 288 media titles]
2024-10-29 11:24
Most Read
Alpha Trading Cup 2024 Award Night: Top Trader Achieves Remarkable 315% Profit, as Over 1,149 Competitors Vie for USD 44,000 Prize Pool
2024-10-25 18:29
8610
International Golo Mori Jazz 2024: Experience the Harmony of Eastern Indonesia's Exotic Beauty and Romantic Jazz Music
2024-10-25 22:48
7462
Infobip and Singtel Partner to Advance Customer Engagement for Singapore Businesses with Rich Communication Services
2024-10-25 12:30
7039
Global development relies on cooperation
2024-10-25 12:38
6056
Peak Energy CEO Gavin Adda Speaks at Asia Clean Energy Summit 2024
2024-10-25 18:30
5759
